Dysregulation of Tissue Factor, Thrombin-Activatable Fibrinolysis Inhibitor, and Fibrinogen in Patients Undergoing Total Joint Arthroplasty
|
|
- Amberlynn Morgan
- 6 years ago
- Views:
Transcription
1 Original Article Dysregulation of Tissue Factor, Thrombin-Activatable Fibrinolysis Inhibitor, and Fibrinogen in Patients Undergoing Total Joint Arthroplasty Clinical and Applied Thrombosis/Hemostasis 2017, Vol. 23(8) ª The Author(s) 2017 Reprints and permission: sagepub.com/journalspermissions.nav DOI: / journals.sagepub.com/home/cat Christopher Wanderling, BSc 1, Jeffrey Liles, MSc 1, Elissa Finkler, MD 2, Peter Carlsgaard, MD 1, William Hopkinson, MD 2, Nil Guler, MD 3, Debra Hoppensteadt, PhD 3, and Jawed Fareed, PhD 3 Abstract Total joint arthroplasty (TJA) of the hip or knee (THA, TKA) has become an increasingly common procedure. While TJA is a successful treatment for individuals experiencing degenerative joint diseases, it is well known that one of the most common perioperative complications of TJA is deep venous thrombosis (DVT). To profile tissue factor (TF), microparticle-tissue factor (MP-TF), thrombin-activatable fibrinolysis inhibitor (TAFI), and fibrinogen levels in patients undergoing TJA to determine potential preexisting Hemostatic dysregulation. De-identified blood samples were obtained from patients undergoing TJA 1 day pre- and 1 day postprocedure. Plasma samples were analyzed using enzyme-linked immunosorbent assay kits for fibrinogen, TAFI, TF, and MP-TF; fibrinogen levels were also assessed using a clot-based activity assay. In comparison with healthy controls, there were significant increases of fibrinogen and MP-TF levels, while there were significant decreases in TF and TAFI levels in the preoperative and postoperative patients. Comparing the pre versus postoperative patients, no significant differences were found; interestingly, however, surgical intervention exacerbated the changes found in the preoperative samples compared to the controls. The results of this study confirm that patients undergoing TJA have preexisting alterations in the fibrinolytic system. Surgical intervention tended to exacerbate these changes. The alterations observed in this study may provide insight as to why TJA is associated with higher rates of DVT and thromboembolism. Keywords arthroplasty, inflammation, coagulation, fibrinolysis Introduction Degenerative joint disease (DJD) is one of the most common medical ailments worldwide. The prevalence of DJD, particularly of the knee, has been estimated to be between 19.2% and 27.8% in individuals 45 years and increases to 37% in individuals >60 years. 1 Once standard medical therapy (nonsteroidal anti-inflammatory drug use, intra-articular corticosteroid injection) is no longer effective in the symptomatic management of DJD, surgical intervention total joint arthroplasty (TJA) is commonly performed. With an aging population, DJD is becoming increasingly prevalent, thus leading to more TJA procedures performed. It is predicted that by 2030, there will be over 4 million TJA procedures performed. 2 While there is a high success rate of TJA in the symptomatic treatment of DJD, this surgical intervention does not come without risk. It has been observed that orthopedic surgeries, in particular TJA, are associated with higher rates of postoperative venous thromboembolism (VTE) such as deep venous thrombosis (DVT) and pulmonary embolism as well as bleeding events. 3,4 It is well known that orthopedic surgeries have higher rates of VTE than procedures performed for other surgical procedures such as in obstetrics and gynecology, general surgery, and cardiothoracic procedures. It is not well understood as to why these postoperative coagulopathies occur at a higher incidence in TJA. Some have hypothesized that these patients have intrinsic, preexisting alterations in their coagulation profiles. Several fibrinolytic biomarkers have previously been identified as being altered in patients undergoing TJA. 5 1 Stritch School of Medicine, Loyola University of Chicago, Maywood, IL, USA 2 Department of Orthopedics, Loyola University Medical Center, Maywood, IL, USA 3 Department of Pathology, Loyola University Medical Center, Maywood, IL, USA Corresponding Author: Christopher Wanderling, Stritch School of Medicine, Loyola University of Chicago, 49 Deerpath Ln, LaGrange Park, Maywood, IL 60526, USA. cwanderling@luc.edu
2 968 Clinical and Applied Thrombosis/Hemostasis 23(8) The current postoperative standard of care differs between institutions and may include ASA administration only or incorporate the use of various anticoagulant therapies such as tranexamic acid (TXA) or heparins. However, it is the accepted standard of practice that postoperative prophylactic anticoagulant therapy be continued for at least 10 days following surgery. 4,6-8 The aim of this study was to profile several components of hemostasis that may also influence the inflammatory process of DJD. This study examined tissue factor (TF), microparticle-tissue factor (MP-TF), fibrinogen, and thrombinactivatable fibrinolysis inhibitor (TAFI). Tissue factor initiates the extrinsic coagulation cascade leading to the activation of the common coagulation pathway and conversion of fibrinogen to fibrin. Upregulation of TF synthesis has been observed to occur in response to inflammation, thus potentially creating a hypercoagulable state. 9 Both TF and fibrin have been identified on synovial tissue; fibrin deposition at the synovium has been demonstrated to potentiate local inflammation. 10 Microparticles are vesicular structures derived from platelets, monocytes, endothelial cells, smooth muscle cells, and tumor cells. Only a small fraction of microparticles in the blood express TF. 11 The MP-TF, acting just as TF, can initiate blood coagulation. 12 Fibrinogen is one of the major components of the coagulation cascade and is also observed to be an acute phase reactant. Fibrinogen is acted upon by thrombin via proteolytic cleavage to yield insoluble fibrin, which is the ultimate product of the coagulation cascade. Activated fibrin binds to platelets, forming a platelet fibrin meshwork clot. 13,14 While thrombin is mainly known to activate fibrinogen to fibrin, it also concomitantly activates TAFI. The main function of TAFI is to stabilize the fibrin platelet clot by inhibiting clot lysis. 15 Thrombin-activatable fibrinolysis inhibitor circulates in plasma as a plasminogen-bound zymogen that is activated by thrombin. Once activated, TAFI inhibits the activation of fibrinolytic activity by the removal of fibrin C-terminal residues via carboxypeptidase activity. 16,17 Not only does TAFI inhibit fibrinolysis, but it may also reduce the inflammation by inactivating kinins and anaphylatoxins, 18 a mechanism that may relate to the pathophysiology of DJD. This study is based on previous evidence of hemostatic dysregulation in TJA patients and it is the primary hypothesis of this study that the biomarkers investigated here will show altered levels in these TJA patients when compared to healthy controls. Furthermore, this study represents the first assessment of these biomarkers in TJA patients and therefore it represents an exploratory investigation and does not include a prospective statistical power and sample size assessment. Patients and Methods This study was designed to compare the circulating levels of various plasma biomarkers of hemostatic dysregulation in DJD patients in comparison to normal healthy controls. Deidentified blood samples were obtained from 45 patients undergoing TKA (n ¼ 27) or THA (n ¼ 18) day 1 preoperatively and day 1 postoperatively. The patient ages ranged from 48 to 85 years, with a mean age of 64.9 (10.5) years. Patient blood samples were collected into tubes containing 3.2% sodium citrate, and plasma was then isolated. Patient and control plasma samples were stored at 80 C. In order to reduce repeated freeze thaw cycles, patient plasma samples were aliquoted into separate tubes. Citrated plasma samples from healthy individuals (n ¼ 8, ages 18-35, nonsmokers) were obtained from George King Biomedical, Inc (Overland Park, Kansas) to serve as controls. Plasma samples were analyzed via ELISA kits for TF, MP-TF, fibrinogen, and TAFI levels (Hyphen Biomed, Neuville-sur- Oise, France). Fibrinogen clot based activity was analyzed on the ACL300plus (Dade Innovin reagents, Erlangen, Germany). Based on the available information, the chart review indicated that these patients were asked not to take any anticoagulant or antiplatelet medications for 1 week prior to surgery. This study was approved by the institutional review board of Loyola University Chicago Health Sciences Division. Patients undergoing TJA revision were excluded from this study. Statistical Analysis Data were analyzed using the Microsoft Excel and in Graphpad Prism Software version 6. The results were expressed as mean (standard deviation). Comparisons between groups were evaluated using the nonparametric Mann-Whitney U test used for nonnormally distributed quantitative data. Correlation analysis was carried out using the nonparametric Spearman test. P values less than.05 were considered statistically significant. Results Measured values for the control, preoperative, and postoperative samples for fibrinogen activity and antigen, TF, MP-TF, and TAFI as well as the percentage changes for each biomarker are presented in Table 1. Figures 1-4 show the box plots for each of the investigated thrombotic and fibrinolytic biomarkers, respectively. There were significant differences in TF and MP-TF levels between the control samples and both the preoperative and postoperative samples; however, the changes were opposite of one another. TF levels were lower in both the preoperative (P <.0001) and the postoperative (P <.0001) samples compared to controls. Tissue factor levels were the same in preoperative and postoperative samples (P ¼.1208). The levels of MP-TF exhibited the opposite change. Compared to the controls, MP-TF levels were increased in the preoperative (P ¼.0400) and in the postoperative (P ¼.0160) patients. While levels in the postoperative samples were marginally elevated compared to the preoperative samples, the difference was not statistically significant (P ¼.3822). There were significant increases in both the fibrinogen antigen (control vs pre, P ¼.0016; control vs post, P ¼.0253) and fibrinogen activity (control vs pre, P ¼.0054; control vs post, P ¼.0001) in patients compared to controls. However, there
3 Wanderling et al 969 Table 1. Control, Preoperative, and Postoperative Values and Percentage Change for the Measured Thrombotic Biomarkers, Tissue Factor (TF), Microparticles-Tissue Factor (MP-TF), Fibrinogen Activity and Antigen, and Thrombin-Activatable Fibrinolysis Inhibitor (TAFI). Control (C) Preoperative Postoperative Preoperative Versus Postoperative TF (pg/ml) (184.9) (38.6) 22.4 (26.82) (38.14) MP-TF (pg/ml) 0.32 (0.20) 0.48 (0.22) 0.64 (0.57) (146.4) Fibrinogen antigen (mg/dl) (52.18) (174.3) (187.6) 4.41 (30.42) Fibrinogen activity (mg/dl) (27.37) (98.25) (147.7) (59.31) TAFI (%) (22.59) (28.85) (28.44) 3.11 (18.66) Figure 1. Box plot showing median levels of tissue factor (TF) measured in control, preoperative, and postoperative groups. Boxes show interquartile ranges and I bars demonstrate highest and lowest values. Figure 3. Box plot showing median levels of thrombin-activatable fibrinolysis inhibitor (TAFI) measured in control, preoperative, and postoperative groups. Boxes show interquartile ranges and I bars demonstrate highest and lowest values. Figure 2. Box plot showing median levels of microparticles-tissue factor (MP-TF) measured in control, preoperative, and postoperative groups. Boxes show interquartile ranges and I bars demonstrate highest and lowest values. was not a significant difference between the preoperative and postoperative samples (antigen, P ¼.5948; activity, P ¼.2957). TAFI levels were significantly lower in both the preoperative (P ¼.0015) and postoperative (P ¼.0037) samples compared to the controls; no difference in mean TAFI levels between the preoperative and postoperative samples (P ¼.7415) was observed. The impact of clinical parameters, such as type of surgery, diabetes, drug use, gender, and so on, on the levels of Figure 4. Box plot showing median levels of fibrinogen antigen (gray) and activity (white) measured in control, preoperative, and postoperative groups. Boxes show interquartile ranges and I bars demonstrate highest and lowest values. thrombotic and fibrinolytic biomarkers was assessed. The only significant correlation observed was between body mass index (BMI) and preoperative levels of fibrinogen activity (P ¼.0237, Spearman r ¼.3446) shown in Figure 5. The results of this study coincide with the results of previous studies performed in this laboratory the previous studies demonstrated that TJA patients have preexisting alterations in
4 970 Clinical and Applied Thrombosis/Hemostasis 23(8) Figure 5. Scatter plot demonstrating the positive correlation as measured by the Spearman correlation coefficient (r ¼.346, P ¼.0237). the fibrinolytic cascade, which may preclude them to VTE or bleeding events. Those results are consistent with the findings of this study. 5,19 Of the 45 TJA patients who participated in this study, 23 were anticoagulated with TXA perioperatively; there was no difference in the measured values for the studied biomarkers. Discussion Previous studies examining the aspects of coagulation and fibrinolysis in patients undergoing TJA have found that there is a tendency for these patients to show alterations of the coagulation and fibrinolytic biomarkers. 19,20 One such study reported that patients undergoing TJA had a preexisting, profibrinolytic profile as demonstrated by alterations in D-dimer and antiplasmin. 19 The results of that study are consistent with the findings in this study. Although there is an increased risk of thrombus formation as demonstrated by the elevated fibrinogen and MP-TF, the stability of the clots may be diminished, due to decreased TAFI and TF levels. The results from this study as well as previous studies demonstrate that patients undergoing TJA may inherently have an elevated risk of perioperative thrombus formation in addition to a bleeding diathesis due to diminished clot stability. This study examined both the antigenic and activity levels of fibrinogen. While there were increases of both antigen and activity levels in the patients undergoing TJA, there was not a difference in the activity: antigen ratio in the controls (1.38 [0.19]), compared to preoperative (1.27 [17.52], P ¼.65) and postoperative (1.24 [0.42], P ¼.21), nor when comparing preoperative versus postoperative levels (P ¼.22). This means that there is not a qualitative change in the fibrinogen synthesized in the patients undergoing TJA. Interestingly, while TF was greatly decreased in the patients undergoing TJA, MP-TF demonstrated a mild, yet significant, increase. It was hypothesized that TF levels should be elevated in these patients because it is associated with coagulation, angiogenesis, and inflammation. 5 This observation may be explained by the fact that the deterioration seen in osteoarthritis is so progressive that, rather than the larger TF molecule being exposed in blood, the MP-TF is elevated due to micro-insults to the synovium that accrue over time. An alternate hypothesis could be that TF is consumed during thrombogenesis, therefore providing falsely decreased measured values. Additionally, the observation that TF levels were lower in patients undergoing TJA than in the controls may be explained by increases in tissue factor pathway inhibitor (TFPI) brought about by upregulation of the inflammatory process. 5 While Basavaraj et al showed that TF is regulated by TFPI on monocytes, it is possible that a similar process may also occur on endothelial cells or synovium in DJD as well as during other inflammatory states. It is also possible that TFPI, while holding a regulatory role in the TF coagulation pathway, may not interact with TF when it is embedded in the membrane of microparticles. Since there are several factors that contribute to the balance between TF and MP-TF levels, it is difficult to project the differential role of these biomarkers in the overall pathogenesis of DJD. Generated TF has a relatively short half-life and readily complexes with factor VII and other cell surfaces, therefore the observed lower level of measurable TF reflects its consumption in the mediation of thrombogenesis or hemostatic process. While the main function of TAFI is to inhibit fibrinolysis via thrombus stabilization, it has also been implicated in reducing inflammation. 18 In this study, it was shown that patients undergoing TJA possess decreased levels of TAFI, which predisposes these patients to increased fibrinolysis and inflammation. Since there is decreased ability to stabilize the thrombi, this alteration may provide insight as to why there are higher rates of thromboembolism and perioperative blood loss. The biomarkers of interest in this study were compared not only against each other but also with the clinical information of these patients. No correlations were identified with this information except for the positive correlation between fibrinogen activity and BMI. This finding is consistent with previous work which demonstrated that body fat was directly correlated with fibrinogen levels. 21 Furthermore, it would make sense that these patients, many of whom have elevated BMI (33.8 [8.2]), would have an elevated fibrinogen level. While the patients undergoing TJA are treated with multiple medications, in this study, the anticoagulant and antiplatelet drugs were stopped 1 week prior to the surgery. The possibility of the use of other pharmacologic agents, such as antihypertensives, diabetic medications, and antibiotics, along with other agents that are widely used cannot be ruled out. It is unlikely that such nonanticoagulant drugs taken by the patients who participated in this study would have any impact on the biomarker levels studied. Conclusion DJD is a disorder affecting millions of individuals worldwide. Medical treatment remains the first line management; however,
5 Wanderling et al 971 many patients ultimately resort to surgical intervention in the form of TJA. Although highly successful in permitting patients to regain function coupled with reduction or elimination of pain, there is an inherent risk of perioperative coagulopathy. While orthopedic surgeries, TJA in particular, are associated with DVT and thromboembolism, it may be that there is a continuous thrombosis fibrinolysis cycle that causes thrombus formation and adhesion followed by embolization. This study s relevance lies in the potential to identify preexisting alterations in the hemostatic profiles of patients undergoing either TKA or THA and work toward normalizing coagulopathies in at-risk patients to reduce their risk of perioperative complications. Limitations One of the major limitations of this study was the lack of agematched controls for comparison. While these control samples ranged from 18 to 35 years and our patient population had a mean age of 64.9 years, this should not discount the findings that patients undergoing TJA have preexisting dysregulation of the coagulation and fibrinolytic systems. While previous studies found that TF, fibrinogen, and TAFI have been positively correlated with age, this should not minimize the findings observed in this study either ; particularly since these findings were observed in females opposed to both males and females in general. Future studies involving age-matched controls may build on the findings presented here. Additionally, it may be of interest as to the information regarding postoperative DVT or VTE development. Unfortunately, this information was unavailable to be examined during this study. Acknowledgments The authors gratefully acknowledge the technical support from the staff of the hemostasis and thrombosis laboratories for facilitating the logistics of the blood collection, storage, and the analysis of the samples included in this study. This research was a part of Students Training in Approaches to Research (STAR) program for medical students. We are thankful to Dr Gail Hecht and Dean Brubaker for their support and encouragement during this study. We are also thankful to Dr Wojick for providing support and resources to conduct this study. Declaration of Conflicting Interests The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Funding The author(s) received no financial support for the research, authorship, and/or publication of this article. References 1. Zhang Y, Jordan JM. Epidemiology of osteoarthritis. Clin Geriatr Med. 2010;26(3): Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to J Bone Joint Surg Am. 2007;89(4): Fujita Y, Nakatsuka H, Namba Y, et al. The incidence of pulmonary embolism and deep vein thrombosis and their predictive risk factors after lower extremity arthroplasty: a retrospective analysis based on diagnosis using multidetector CT. J Anesth. 2015;29(2): SunQ,YuX,NieX,GongJ,CaiM.Theefficacycomparison of tranexamic acid for reducing blood loss in total knee arthroplasty at different dosage time. J Arthroplasty. 2017;32(1): Guler N, Burleson A, Syed D, et al. Fibrinolytic dysregulation in total joint arthroplasty patients: potential clinical implications. Clin Appl Thromb Hemost. 2016;22(4): Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl JMed. 2008;358(26): Nurmohamed MT, Rosendaal FR, Büller HR, et al. Low-molecularweight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet. 1992;340(8812): Anderson DR, Dunbar MJ, Bohm ER, et al. Aspirin versus lowmolecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med. 2013;158(11): Camerer E, Kolstø AB, Prydz H. Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res. 1996;81(1): Busso N, Morard C, Salvi R, Péclat V, So A. Role of the tissue factor pathway in synovial inflammation. Arthritis Rheum. 2003; 48(3): Zwicker JI, Trenor CC, Furie BC, Furie B. Tissue factor-bearing microparticles and thrombus formation. Arterioscler Thromb Vasc Biol. 2011;31(4): Morel O, Toti F, Hugel B, et al. Procoagulant microparticles: disrupting the vascular homeostasis equation? Arterioscler Thromb Vasc Biol. 2006;26(12): Lowe GD, Rumley A, Mackie IJ. Plasma fibrinogen. Ann Clin Biochem. 2004;41(pt 6): Weisel JW. Fibrinogen and fibrin. Adv Protein Chem. 2005;70: Bouma BN, Mosnier LO. Thrombin activatable fibrinolysis inhibitor (TAFI) how does thrombin regulate fibrinolysis? Ann Med. 2006;38(6): Boffa MB, Reid TS, Joo E, Nesheim ME, Koschinsky ML. Characterization of the gene encoding human TAFI (thrombinactivable fibrinolysis inhibitor; plasma procarboxypeptidase B). Biochemistry. 1999;38(20): Zhao L, Morser J, Bajzar L, Nesheim M, Nagashima M. Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms. Thromb Haemost. 1998;80(6): Craven S, Dewar L, Yang X, Ginsberg J, Ofosu F. Altered regulation of in-vivo coagulation in orthopedic patients prior to knee or hip replacement surgery. Blood Coagul Fibrinolysis. 2007; 18(3): Myles T, Nishimura T, Yun TH, et al. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem. 2003;278(51):
6 972 Clinical and Applied Thrombosis/Hemostasis 23(8) 20. Basavaraj MG, Gruber FX, Sovershaev M, et al. The role of TFPI in regulation of TF-induced thrombogenicity on the surface of human monocytes. Thromb Res. 2010;126(5): Bo M, Raspo S, Morra F, Cassader M, Isaia G, Poli L. Body fat is the main predictor of fibrinogen levels in healthy non-obese men. Metabolism. 2004;53(8): Ariëns RA, Coppola R, Potenza I, Mannucci PM. The increase with age of the components of the tissue factor coagulation pathway is gender-dependent. Blood Coagul Fibrinolysis. 1995; 6(5): Fu A, Nair KS. Age effect on fibrinogen and albumin synthesis in humans. Am J Physiol. 1998;275(6 pt 1):E1023-E Juhan-Vague I, Renucci JF, Grimaux M, et al. Thrombinactivatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2000;20(9):
This paper reviews the potential cost-effectiveness
n reports n Cost-Effectiveness of Rivaroxaban After Total Hip or Total Knee Arthroplasty Louis M. Kwong, MD, FACS Abstract Venous thromboembolism (VTE) following joint replacement surgery represents an
More informationAdv Pathophysiology Unit 4 Page 1 of 10. Learning Objectives for this file:
Adv Pathophysiology Unit 4 Page 1 of 10 Learning Objectives for this file: Topics include structure & function of: 1. Coagulation process platelets, clotting factors 2. Coagulation cascade formation of
More informationVenous thromboembolism (VTE) Can Biomarkers Help to Guide Duration of Therapy After VTE? New Chest Guidelines 2016
Venous thromboembolism (VTE) Can Biomarkers Help to Guide Duration of Therapy After VTE? Marlene Grenon, MD Associate Professor of Surgery University of California San Francisco UCSF Vascular Surgery Symposium
More informationOmar A. Elkashef, MD
DVT Prophylaxis in Orthopedic Surgery By Omar A. Elkashef, MD Kasr Al- aini About VTE Venous thromboembolism encompasses deep vein thrombosis (DVT) and pulmonary embolism VTE is common and PE is a potentially
More informationLOW MOLECULAR WEIGHT HEPARIN THE STANDARD VALUE
LOW MOLECULAR WEIGHT HEPARIN THE STANDARD VALUE ANASTASIOS V. KOROMPILIAS, MD ORTHOPAEDIC DEPARTMENT, MEDICAL SCHOOL UNIVERSITY OF IOANNINA, IOANNINA, GREECE MAJOR ORTHOPAEDIC SURGERY POSTOPERATIVE CLASSIFIED
More informationVenous Thromboembolism Prophylaxis after Major Elective Orthopedic Surgery
Venous Thromboembolism Prophylaxis after Major Elective Orthopedic Surgery Tony Wan, MD, FRCPC Clinical Instructor, Division of General Internal Medicine Department of Medicine, University of British Columbia
More informationCoagulopathy Case-2. Andy Nguyen, M.D. 2009
Coagulopathy Case-2 Andy Nguyen, M.D. 2009 CLINICAL HISTORY A 42 year-old man brought to the emergency room with severe burn. Patient was rescued by firemen in a serious fire. He had been found unconscious
More informationDOACs: When and how to measure their anticoagulant effect
DOACs: When and how to measure their anticoagulant effect Stavroula Tsiara MD, PhD, FRCP Associate Professor of Internal Medicine University of Ioannina, Greece NOACs NOACs, TSOACs, DOACs (ISTH) Target
More informationLVHN Scholarly Works. Lehigh Valley Health Network. Joseph G. Ottinger RPh, MS, MBA, BCPS Lehigh Valley Health Network,
Lehigh Valley Health Network LVHN Scholarly Works Department of Pharmacy Retrospective Evaluation of Delayed Administration of Fondaparinux in Providing Comparable Safety and Efficacy Outcomes in Patients
More informationGeneral Principles of. Hemostasis. Kristine Krafts, M.D.
General Principles of Hemostasis Kristine Krafts, M.D. Hemostasis is a balancing act! pro-ting plugs up holes in blood vessels anti-ting keeps ting under control Pro-Clotting Pro-Clotting vessels platelets
More informationA Pilot Study Comparing Hospital Readmission Rates In Patients Receiving Rivaroxaban or Enoxaparin After Orthopedic Surgery
A Pilot Study Comparing Hospital Readmission Rates In Patients Receiving Rivaroxaban or Enoxaparin After Orthopedic Surgery Melissa A. Herschman, PharmD, BCPS; Frank S. Rigelsky, PharmD, BCPS; and Sandra
More informationISIS PHARMACEUTICALS. ISIS-FXI Rx Program Update. Webcast December 8, 2014
ISIS PHARMACEUTICALS ISIS-FXI Rx Program Update Webcast December 8, 2014 Introduction Stan Crooke, M.D., Ph.D. CEO and Chairman, Isis Pharmaceuticals 2 Forward Looking Language Statement This presentation
More informationPROPHYLAXIS IN THE ORTHOPEDIC PATIENT: Martin H. Ellis MD Hematology Institute and Blood Bank Meir Medical Center Kfar Saba
VENOUS THROMBOEMBOLISM PROPHYLAXIS IN THE ORTHOPEDIC PATIENT: Martin H. Ellis MD Hematology Institute and Blood Bank Meir Medical Center Kfar Saba OVERVIEW Biochemistry of coagulation Pathogenesis of VTE
More informationCoagulation Mechanisms Dr. Nervana Bayoumy
Coagulation Mechanisms Dr. Nervana Bayoumy Associate Professor Department of Physiology Objectives At the end of this lecture you should be able to: 1. Recognize the different clotting factors 2. Understand
More informationThe Lancet Publishes Results from the Landmark Phase III Rivaroxaban Study RECORD2
News Release Bayer HealthCare AG Corporate Communications 51368 Leverkusen Germany Phone +49 214 30 1 www.news.bayer.com Venous Blood Clot Prevention after Hip Replacement Surgery: The Lancet Publishes
More informationEDUCATIONAL COMMENTARY STRAIGHT TALK ABOUT THE D-DIMER
EDUCATIONAL COMMENTARY STRAIGHT TALK ABOUT THE D-DIMER Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits
More informationPlatelet Factor IV- Heparin Antibodies. Presenter: Michael J. Warhol, M.D.
Platelet Factor IV- Heparin Antibodies Presenter: Michael J. Warhol, M.D. Learning Objectives Describe the mechanism of interaction between Heparin and Platelet Factor 4 Review the chemistry of Heparin
More informationStudy population The study population comprised patients undergoing major hip or knee surgery.
Pharmacoeconomic analysis of fondaparinux versus enoxaparin for the prevention of thromboembolic events in orthopedic surgery patients Dranitsaris G, Kahn S R, Stumpo C, Paton T W, Martineau J, Smith R,
More informationCoagulation in perspective: Blood management. Objectives
Coagulation in perspective: Blood management Julie Wegner, PhD jawrbl@gmail.com Objectives To gain a basic understanding of the following: 1. Coagulation components and processes Why patients bleed. 2.
More informationUvA-DARE (Digital Academic Repository) Factor XI as target for antithrombotic therapy van Montfoort, M.L. Link to publication
UvA-DARE (Digital Academic Repository) Factor XI as target for antithrombotic therapy van Montfoort, M.L. Link to publication Citation for published version (APA): van Montfoort, M. L. (2014). Factor XI
More informationScottish Medicines Consortium
Scottish Medicines Consortium fondaparinux, 2.5mg/0.5ml, solution for injection (Arixtra ) No. (287/06) GlaxoSmithKline 7 July 2006 The Scottish Medicines Consortium has completed its assessment of the
More informationNovel Anti-coagulant Agents. David G Hovord BA MB BChir FRCA Clinical Assistant Professor University of Michigan
Novel Anti-coagulant Agents David G Hovord BA MB BChir FRCA Clinical Assistant Professor University of Michigan Objectives Provide an overview of the normal coagulation, including perioperative testing
More informationEDUCATIONAL COMMENTARY D-DIMER UPDATE
EDUCATIONAL COMMENTARY D-DIMER UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits see the Continuing
More informationThese handouts are only meant as a guide while you follow the presentation on the screen. Sometimes the speaker will change some of the slides.
These handouts are only meant as a guide while you follow the presentation on the screen. Sometimes the speaker will change some of the slides. If you would like the 1 slide per page handouts, please ask
More informationDirect anticoagulation therapy
Direct anticoagulation therapy Pan-Arab Meeting & Saudi Society of Hematology Dr Ihab Alhemaidi MBBS MRCP(Lond UK) FRCPath. Fellow of the Royal Society of Medicine Consultant Adult hematology/bmt Section
More informationClinical Study Synopsis
Clinical Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website or on the website www.clinicalstudyresults.org hosted by the Pharmaceutical Research and
More informationPrimary hemostasis. Vascular endothelium Vasoconstriction : local tissue factor, nervous system
Primary hemostasis Vascular endothelium Vasoconstriction : local tissue factor, nervous system Platelet Plug Platelet Adhesion Platelet Activation Platelet Aggregation Platelet Plug Formation Secondary
More informationBivalirudin (Angiomax ) vs. Heparin during Peripheral Vascular Interventions: Which is Better and How to Decide?
Bivalirudin (Angiomax ) vs. Heparin during Peripheral Vascular Interventions: Which is Better and How to Decide? Vinod Nair MD FACC FSCAI Cardiovascular Ins6tute of the South, Houma Financial Disclosure:
More informationROZAIMAH ZAIN-HAMID. Department of Pharmacology and Therapeutics Faculty of Medicine, Universitas Sumatera Utara
ROZAIMAH ZAIN-HAMID Department of Pharmacology and Therapeutics Faculty of Medicine, Universitas Sumatera Utara Drugs Used in Disorders of Coagulation Fibrinolytic drugs Anti-thrombotic thrombotic drugs
More informationSession 1 Topics. Vascular Phase of Hemostasis. Coagulation Pathway. Action of Unfractionated Heparin. Laboratory Monitoring of Anticoagulant Therapy
~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 1 of 4 Session 1 Topics Review of coagulation and the vascular phase of hemostasis Unfractionated heparin Low molecular
More informationPlasma Testing in the Clinical Coagulation Laboratory: New drugs, new problems.
Test Plasma Testing in the Clinical Coagulation Laboratory: New drugs, new problems. Karen A. Moffat BEd, MSc, ART, FCSMLS(D) Technical Specialist, Coagulation, HRLMP Assistant Professor, Department of
More informationNew Anticoagulants Linda Liu, M.D.
Difficult Task New Anticoagulants Professor UCSF Dept of Anesthesia 15 minutes! Emphasis on 2 new oral anticoagulants Dabigatran Rivaroxaban Relation to anesthesia Rapid reversal Regional anesthesia UC
More informationDisclosures. Thromboelastography. TEG Methodology. TEG Output. Thromboelastography (TEG): Basics & Clinical Applications
Thromboelastography (TEG): Basics & Clinical Applications Paula J. Santrach MD Associate Professor, Laboratory Medicine Mayo Clinic Rochester, MN Disclosures Relevant financial relationships NONE Off label
More informationUse of Heparin and The Related Incidence of Heparin- Induced Thrombocytopenia in an Education and Research Hospital in Turkey
VOLUME 8 NUMBER 3 September 2017 JOURNAL OF CLINICAL AND EXPERIMENTAL INVESTIGATIONS ORIGINAL ARTICLE Use of Heparin and The Related Incidence of Heparin- Induced Thrombocytopenia in an Education and Research
More informationEmergency and Perioperative Hemostasis Testing: Which Assays Provide Helpful Information. Wayne Chandler, MD Laboratory Medicine Seattle Children s
Emergency and Perioperative Hemostasis Testing: Which Assays Provide Helpful Information Wayne Chandler, MD Laboratory Medicine Seattle Children s Emergency Hemostasis Testing Patients actively bleeding
More informationHemostasis and Thrombosis
Hemostasis Hemostasis and Thrombosis Normal hemostasis is a consequence of tightly regulated processes that maintain blood in a fluid state in normal vessels, yet also permit the rapid formation of a hemostatic
More informationANTICOAGULANT THERAPY ANTICOAGULANT THERAPY REVISITED Thrombosis is a complication of underaggressive anticoagulant therapy
ANTICOAGULANT THERAPY REVISITED 2004 or, Which one(s) of these (#$%$#!@#^) drugs should be the one(s) I use, and for what? ANTICOAGULANT THERAPY One of most common treatments in hospital & out 2 nd most
More informationChanges in coagulation and tissue plasminogen activator after the treatment of cerebral infarction with lumbrokinase
Clinical Hemorheology and Microcirculation 23 (2000) 213 218 213 IOS Press Changes in coagulation and tissue plasminogen activator after the treatment of cerebral infarction with lumbrokinase Lirong Jin
More informationTransfusion & Non-transfusion Approaches to Bleeding
Transfusion & Non-transfusion Approaches to Bleeding Maureane Hoffman, MD, PhD Professor of Pathology, Duke University and Director, Transfusion Service and Hematology Laboratory Durham Veterans Affairs
More informationSpecial Coagulation - APC Resistance. DiaPharma Group, Inc. Customer Service: Technical Support:
Special Coagulation - APC Resistance DiaPharma Group, Inc. Customer Service: 1.800.526.5224 Technical Support:1.800.447.3846 www.diapharma.com 1 Review of Hemostasis Overview Pathways of coagulation, anticoagulation,
More informationIntroduction Hemostasis: Tourniquet Test & Bleeding Time. Hematology-Immunology System Faculty of Medicine Universitas Padjadjaran LOGO
Introduction Hemostasis: Tourniquet Test & Bleeding Time Hematology-Immunology System Faculty of Medicine Universitas Padjadjaran LOGO Hemostasis A series of reactions that function to stop bleeding, maintaining
More informationLABORATORY APPROACH TO BLEEDING DISORDERS DR NISHANTH PG 1 ST YEAR DEPARTMENT OF PATHOLOGY
LABORATORY APPROACH TO BLEEDING DISORDERS DR NISHANTH PG 1 ST YEAR DEPARTMENT OF PATHOLOGY 1 WHEN IS THE LAB REQUIRED TO INVESTIGATE FOR A POSSIBLE BLEEDING DISORDER? Clinically suspected bleeding tendency
More informationType of intervention Primary prevention. Economic study type Cost-effectiveness analysis.
Cost/death averted with venous thromboembolism prophylaxis in patients undergoing total knee replacement or knee arthroplasty Nerurkar J, Wade W E, Martin B C Record Status This is a critical abstract
More informationHemostasis practice: state-of-the-art
Perspective Page 1 of 6 Hemostasis practice: state-of-the-art Giuseppe Lippi 1, Emmanuel J. Favaloro 2 1 Section of Clinical Biochemistry, Department of Neurological, Biomedical and Movement Sciences,
More informationAnticoagulation in VTE The Haematologist s Perspective. Dr. M.D. Maina FRCP Edin.
Anticoagulation in VTE The Haematologist s Perspective Dr. M.D. Maina FRCP Edin. Disclosures None The coagulation process that leads to haemostasis involves a complex set of reactions involving approximately
More informationUsing TEG in the ED, OR, and ICU. Don H. Van Boerum, MD, FACS
Using TEG in the ED, OR, and ICU Don H. Van Boerum, MD, FACS Trauma Surgeon, Director of Surgical Critical Care, Co-Director of Shock Trauma ICU, Intermountain Medical Center, Intermountain Healthcare
More informationChallenges of VTE Prophylaxis in. Orthopaedics. Prevalence of DVT in Orthopaedic Surgery Without Prophylaxis
Grand Rounds Scripps Green Hospital May 5, 2010 Challenges of VTE Prophylaxis in Orthopaedics C. W. Colwell, Jr., M.D. At Scripps Clinic Challenges of VTE Prophylaxis in Orthopaedics I have a potential
More informationUpdate on the Direct Oral Anticoagulants (DOACs)
Update on the Direct Oral Anticoagulants (DOACs) J. Randle Adair DO, PhD Internal Medicine New Mexico Cancer Center & Co-Chair, Anticoagulation Subcommittee Presbyterian Healthcare Services (PHS) Attending,
More informationNEW ORAL ANTICOAGULANTS FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS IN THE FOOT AND ANKLE
NEW ORAL ANTICOAGULANTS FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS IN THE FOOT AND ANKLE Matthew Q. McCammon, DPM INTRODUCTION Venous thromboembolism (VTE) is a common cause of morbidity and mortality. Each
More informationTiming the First Postoperative Dose of Anticoagulants Lessons Learned From Clinical Trials
[ Commentary ] Timing the First Postoperative Dose of Anticoagulants Lessons Learned From Clinical Trials Jeremy S. Paikin, MD ; Jack Hirsh, MD ; Noel C. Chan, MBBS ; Jeffrey S. Ginsberg, MD ; Jeffrey
More informationHemostasis. by Mohie-Aldien Elsayed
Hemostasis by Mohie-Aldien Elsayed Hemostasis Hemostasis is defined as the process that maintains the flowing blood in a fluid state and confined to the circulatory system Coagulation prevents excess blood
More informationLina Al-Lawama. Rama Al-Ashqar. Malik Al-Zohlof
2 Lina Al-Lawama Rama Al-Ashqar Malik Al-Zohlof Anticoagulant drugs Recap Last lecture we were talking about antiplatelet drugs, we mentioned 5 drugs : Aspirin which is used alone with patents that have
More informationSign up to receive ATOTW weekly
RECOMBINANT HUMAN ACTIVATED PROTEIN C IN THE TREATMENT OF SEVERE SEPSIS ANAESTHESIA TUTORIAL OF THE WEEK 133 11 TH MAY 2009 Dr Richard Eve, Royal Cornwall Hospital, Cornwall, UK Correspondence to richardlloydeve@gmail.com
More informationManejo de la transfusión de plaquetas. Ileana López-Plaza, MD
Manejo de la transfusión de plaquetas Ileana López-Plaza, MD Thrombocytopenia Common in ICU setting 25-38% with< 100,000/µL 2-3 % with < 10,000/µL Common etiologies Drug-induced: heparin, antibiotics,
More information3 : 34. Pankaj Manoria, P C Manoria, Bhopal
3 : 34 Newer Antithrombins and anticoagulants Introduction Thrombosis is a leading cause of morbidity and mortality but for decades, anticoagulant therapy has usually consisted of unfractionate heparin
More informationThrombin Generation Mediators and Markers in Sepsis-Associated Coagulopathy and Their Modulation by Recombinant Thrombomodulin
Original Article Thrombin Generation Mediators and Markers in Sepsis-Associated Coagulopathy and Their Modulation by Recombinant Thrombomodulin Clinical and Applied Thrombosis/Hemostasis 2014, Vol 20(2)
More informationUW Medicine Alternative Monitoring for Antithrombotic Agents
Tags: monitoring alternative monitoring SUMMARY OF ANTICOAGULATION LAB TESTS AT UWMedicine Description Order Code Specimen Collection Availability Turn-Around Time Anti Xa Based Tests antixa for heparin
More informationMembrane microvesicles: a circulating source for fibrinolysis, new antithrombotic
Membrane microvesicles: a circulating source for fibrinolysis, new antithrombotic messengers 1 Laurent Plawinski, 2,3 Eduardo Anglés-Cano 1 CNRS UMR 5248 Imagerie Moléculaire et Nanobiotechnologie, Université
More informationType of intervention Treatment; secondary prevention. Economic study type Cost-effectiveness analysis.
Coagulation disorders induced by L-asparaginase: correction with and without fresh-frozen plasma Glasmacher A, Kleinschmidt R, Unkrig C, Mezger J, Scharf R E Record Status This is a critical abstract of
More informationClinical Procedure. ROTEM Trauma, Resuscitation. Princess Alexandra Hospital Emergency Department. 1 Introduction
Princess Alexandra Hospital Emergency Department Clinical Procedure Trauma, Resuscitation Review Officer: Glenn Ryan 1 Introduction Version no: 1 Approval Date: 16/07/2014 Review Date: 16/07/2016 Authority:
More informationTITLE: Microvesicle Production After Trauma and Its Clinical Impact on Venothromboembolism
Award Number: W81XWH-1-2-11 TITLE: Microvesicle Production After Trauma and Its Clinical Impact on Venothromboembolism PRINCIPAL INVESTIGATOR: Myung S. Park, M. D. CONTRACTING ORGANIZATION: Mayo Clinic
More informationFondaparinux vs. enoxaparin for the prevention of venous thromboembolism after total hip replacement: A meta-analysis
EXPERIMENTAL AND THERAPEUTIC MEDICINE 12: 969-974, 2016 Fondaparinux vs. enoxaparin for the prevention of venous thromboembolism after total hip replacement: A meta-analysis WEN JUN DONG, HUI JUAN QIAN,
More informationUse of modified intention to treat analysis in studies of direct oral anticoagulants and risk of selection bias.
Use of modified intention to treat analysis in studies of direct oral anticoagulants and risk of selection bias. Tristan Rainville, MD, a Madeleine Durand, MD, MSc, b Mikhael Laskine, MD, MSc, b a Centre
More informationProfibrinolytic diabody targeting PAI-1 and TAFI for treatment of acute thrombotic disorders
ProFiDIΛ Profibrinolytic diabody targeting PAI-1 and TAFI for treatment of acute thrombotic disorders THROMBOLYSIS WITH IMPROVED SAFETY A valorisation project of Unmet Medical Need = Safe Thrombolysis
More informationAnticlotting mechanisms 1: physiology and pathology
: physiology and pathology J Adanma Ezihe-Ejiofor FRCA, FWACS, MBBS Nevil Hutchinson FRCA 1A01 Key points Anticlotting mechanisms are important in restricting clot formation to the site of injury. The
More information10/8/2013. Drug-induced immune thrombocytopenia (DITP) Clinical aspects
Richard Aster, MD Blood Center of Wisconsin, Blood Research Institute, Milwaukee, WI Senior Investigator Medical College of Wisconsin Professor, Departments of Medicine & Pathology Drug-induced immune
More informationPeer Review Report # 2. Low Molecular Weight Heparins
20 th Expert Committee on Selection and Use of Essential Medicines Peer Review Report # 2 Low Molecular Weight Heparins (1) Does the application adequately address the issue of the public health need for
More informationBayer R&D Investor Day 2005
Science For A Better Life HealthCare Bayer R&D Investor 25 December 8, 25 London Bayer R&D Investor 25 BAY 59-7939: A Novel, ral, Direct Factor Xa Inhibitor Frank Misselwitz Head of Therapeutic Area Cardiovascular,
More informationThe Role Of Point of Care Coagulation Testing (POCCT) in Patient Blood Management. Elham Khalaf Adeli
The Role Of Point of Care Coagulation Testing (POCCT) in Patient Blood Management Elham Khalaf Adeli Overview PBM, bleeding management, Coagulation POC Testing Review of laboratory conventional coagulation
More informationDr. Andrew Kotaska YELLOWKNIFE NT 221 VENOUS THROMBOEMBOLISM PROPHYLAXIS: WHO REALLY NEEDS SNAKE OIL?
Society of Rural Physicians of Canada 26TH ANNUAL RURAL AND REMOTE MEDICINE COURSE ST. JOHN'S NEWFOUNDLAND AND LABRADOR APRIL 12-14, 2018 Dr. Andrew Kotaska YELLOWKNIFE NT 221 VENOUS THROMBOEMBOLISM PROPHYLAXIS:
More informationAntithrombosis Management for Pediatric VAD and Beyond
Antithrombosis Management for Pediatric VAD and Beyond Christina VanderPluym M.D. Director of Ventricular Assist Device and Cardiac Antithrombosis Program Boston Children s Hospital, USA Disclosures I
More informationUse of Chromogenic Assay of Factor X to Accept or Reject INR Results in Warfarin Treated Patients
CM&R Rapid Release. Published online ahead of print July 22, 2009 as Use of Chromogenic Assay of Factor X to Accept or Reject INR Results in Warfarin Treated Patients Michael J. Sanfelippo, MS, MT ASCP;
More informationManaging the Risks Associated with Anticoagulant Therapy. Steve McGlynn Specialist Principal Pharmacist (Cardiology) NHS Greater Glasgow and Clyde
Managing the Risks Associated with Anticoagulant Therapy Steve McGlynn Specialist Principal Pharmacist (Cardiology) NHS Greater Glasgow and Clyde Background Identified as high risk medicines Wide range
More informationPrincess Alexandra Hospital Emergency Department. Clinical Procedure. 1 Introduction
Princess Alexandra Hospital Emergency Department Clinical Procedure Trauma, Resuscitation Review Officer: Glenn Ryan 1 Introduction Version no: 1 Approval Date: 16/07/2014 Review Date: 16/07/2016 Authority:
More informationVenous thromboembolism (VTE) comprises deepvein
At a Glance Original Research Practical Implications p 107 Author Information p 110 Full text and PDF www.ajpblive.com Economic Model Comparing Rivaroxaban and Enoxaparin for Post-Orthopedic VTE Prophylaxis
More informationa unit of Dr Bharat S Mody Director Chief Arthroplasty Surgeon Centre for Knee & Hip Surgery Dr Pankaj Patni Orthopaedic Surgeon Dr Sunil Dewangan
Centre for Knee & Hip Surgery Arthroscopy a unit of Arthroplasty Dr Bharat S Mody Director Chief Arthroplasty Surgeon Dr Sunil Dewangan Dr Prakash Tekwani Dr Rahul Khanna Dr Pankaj Patni Orthopaedic Surgeon
More informationSYNOPSIS. Clinical Study Report for Study CV Individual Study Table Referring to the Dossier
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Individual Study Table Referring to the Dossier (For National Authority Use Only) Name of Active Ingredient: SYNOPSIS Clinical Study
More informationContinuing Education for Pharmacists
Continuing Education for Pharmacists Oral anticoagulation without protimes: A review of two emerging agents that may come to market. Lindsay Davis, Pharm.D. (Acute Care Pharmacy Resident, Phoenix VA Medical
More informationType of intervention Secondary prevention. Economic study type Cost-effectiveness analysis.
Comparison of the cost of preventing postoperative deep vein thrombosis with either unfractionated or low molecular weight heparin Bergqvist D, Lindgren B, Matzsch T Record Status This is a critical abstract
More informationPerson responsible (Chair): Martine Jandrot-Perrus, Hans Deckmyn
NAME OF PROJECT: Measurement of platelet activation markers: usefulness, current practices, future. Subcommittee: Platelet physiology Person responsible (Chair): Martine Jandrot-Perrus, Hans Deckmyn Design:
More informationBevyxxa (betrixaban) NEW PRODUCT SLIDESHOW
Bevyxxa (betrixaban) NEW PRODUCT SLIDESHOW Introduction Brand name: Bevyxxa Generic name: Betrixaban Pharmacological class: Factor Xa inhibitor Strength and Formulation: 40mg, 80mg; caps Manufacturer:
More informationMouse Alpha-2-Antiplasmin Total ELISA Kit
Mouse Alpha-2-Antiplasmin Total ELISA Kit Catalog No: IMA2APKT-TOT Lot No: 413 INTENDED USE This mouse α2-antiplasmin assay is for the quantitative determination of total α2-antiplasmin in mouse plasma.
More informationASSAY METHODS FOR THE EXPLORATION OF FIBRINOLYSIS
ASSAY METHODS FOR THE EXPLORATION OF FIBRINOLYSIS Jean AMIRAL, President HYPHEN BioMed (France) Fibrinolysis Functions Neurology (brain) Fertility Cell Remodelling FIBRINOLYSIS Malignancy (metastasis)
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Fragmin) Reference Number: CP.PHAR.225 Effective Date: 05.01.16 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder
More informationManaging Coagulation Abnormalities Linda Liu, M.D.
Managing Coagulation Abnormalities Professor UCSF Dept of Anesthesia UC SF 1 Difficult Task Coagulation Abnormalities 30 minutes Emphasis on 2 new oral anticoagulants Dabigatran Rivaroxaban UC SF 2 UC
More informationHuman D- dimer ELISA Kit
Product Manual Human D- dimer ELISA Kit Catalog Numbers PRB- 5048 PRB- 5048-5 96 assays 5 x 96 assays FOR RESEARCH USE ONLY Not for use in diagnostic procedures Introduction Thrombosis is the local coagulation
More informationDEPARTMENT OF CLINICAL LABORATORY SCIENCES SCHOOL OF HEALTH TECHNOLOGY AND MANAGEMENT THE UNIVERSITY AT STONY BROOK STONY BROOK, NEW YORK
DEPARTMENT OF CLINICAL LABORATORY SCIENCES SCHOOL OF HEALTH TECHNOLOGY AND MANAGEMENT THE UNIVERSITY AT STONY BROOK STONY BROOK, NEW YORK 11794-8205 COAGULATION COMPETENCY EVALUATION FORM STUDENT NAME:
More informationCoagulation Cascade. TF-VIIa. Tissue Factor + VII. XIIa. Prothrombin. XIa. IXa. VIIIa. Thrombin. XL- Fibrin. XIII Monomer. Fibrinogen.
Coagulation Cascade Intrinsic Pathway Extrinsic Pathway Contact Activation XIIa XI XIa Prekallikrein HMW Kininogen IX IXa Ca 2+ Anticoagulation proteins: Protein C, Protein S, Antithrombin III, TFPI TF
More informationHemostasis/Thrombosis IV
Hemostasis/Thrombosis IV Antithrombotic Therapy Antithrombotic Therapy Mainstay of battle against thromboembolic disease Hot area of new drug research Cannot inhibit clot formation without increased risk
More informationReal-world data confirm clinical trial outcomes for rivaroxaban in orthopaedic patients
REVIEW ARTICLE Real-world data confirm clinical trial outcomes for rivaroxaban in orthopaedic patients Louis Kwong, MD a and Alexander G.G. Turpie, MD, FRCP, FACP, FACC, FRCPC b a Department of Orthopaedic
More informationAlternative Haemostatic Agents in the Management of Obstetric Haemorrhage
Alternative Haemostatic Agents in the Management of Obstetric Haemorrhage Clinical Associate Professor Nolan McDonnell School of Medicine and Pharmacology, School of Women s and Infants Health University
More informationMehta Hiren R et al. IRJP 2 (4)
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY ISSN 2230 8407 Available online http://www.irjponline.com Review Article XIMELAGATRAN: A NEW DIRECT THROMBIN INHIBITOR Mehta Hiren R 1 *, Patel Paresh B 2, Galani
More informationEnoxaparin 1 mg/kg twice daily as a bridge to
Once Daily Enoxaparin for Outpatient Treatment of Acute Venous Thromboembolism: A Case-control Study Clinical and Applied Thrombosis/Hemostasis Volume 16 Number 1 January/February 2010 21-25 # 2010 The
More informationImmunomodulation at Cardiac Surgery. William T McBride MD
Immunomodulation at Cardiac Surgery William T McBride MD March 2005 Basic Structure of Immune System Immune response Adaptive specific memory Innate non-specific no memory ADAPTIVE (specific) b INNATE
More informationTHE MICHELANGELO OASIS 5 PROGRAM. MichelAngelo : The Creation of Man (Fragment of the Sistine Chapel ceiling- Detail) ( )
THE MICHELANGELO OASIS 5 PROGRAM MichelAngelo : The Creation of Man (Fragment of the Sistine Chapel ceiling- Detail) (1511-12) Key Steps in Coagulation Pathway Intrinsic pathway Extrinsic pathway 1 Xa
More informationDOACs Can Be Reversed!
1 DOACs Can Be Reversed! AC Forum 14 th National Conference April 21, 2017 Adam Cuker, MD, MS Perelman School of Medicine University of Pennsylvania 2 Full disclosures (last 12 months) Research support
More informationManagement of Bleeding in the Anticoagulated Patient Short Snappers CSIM 2015 Elizabeth Zed, MD, FRCPC October 17, 2015
+ Management of Bleeding in the Anticoagulated Patient Short Snappers CSIM 2015 Elizabeth Zed, MD, FRCPC October 17, 2015 + Disclosures Off label use of PCC and apcc will be discussed My centre participates
More informationPharmacology Lecture 5. Anticoagulants
Pharmacology Lecture 5 Anticoagulants General overview Anti-thrombotic Drugs Antiplatlets Anticoagulants Fibrinolytics Anticoagulants Indirect Thrombin Inhibitors Anti-thrombotic effect is exerted by interaction
More informationMedical Staff, House Staff, Patient Care Centers, Outpatient Clinics and UC Med Labs Clients
TO: FROM: Medical Staff, House Staff, Patient Care Centers, Outpatient Clinics and UC Med Labs Clients Krzysztof Mikrut, B.S. MT (ASCP) Technical Director, Coagulation Laboratory Jonathan L. Miller, M.D.,
More informationRat Tissue-type Plasminogen Activator (tpa) Total Antigen ELISA
Package Insert Rat Tissue-type Plasminogen Activator (tpa) Total Antigen ELISA 96 Wells For Research Use Only v. 1.0 Eagle Biosciences, Inc. 20A NW Blvd., Suite 112, Nashua, NH 03063 Phone: 866-419-2019
More information